Search results for: Market Access
Filter search results
Managing the NHS: past, present and agenda for the future
1 March 1994
…paper shows, the internal market reforms cannot be seen simply as an aberration in the administrative development of the NHS. In many respects they can be seen as the logical…
The UK Biotech Sector and Brexit: Past Performance and Future Prospects
1 April 2018
…firms that do exist have not brought blockbuster drugs to the market and (3) what the implications are for industrial strategy after Brexit. These remarks are based primarily on research…
A Critique of the Paper “The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List”
1 May 2018
…cost estimates and the removal of patent protection in the context of on-patent drugs. However, in many markets some recovery of R&D cost is both to be expected and is…
The Impact of New Medicines in the NHS: 70 Years of Innovation
1 August 2018
…Through interviews with experts we identified a shortlist of the most important medicines to have been brought to market, and from a review of the literature and evidence base we…
Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers
1 June 2022
…will impact biopharmaceutical companies’ incentives to innovate. However, the magnitudes and timings of impacts on the numbers of new drugs coming to market are unclear. To inform policymaking in this…
G7 Investments in New Antibiotics Would Pay Off – For Everyone
9 December 2022
…market over the next three decades, targeted at the six priority pathogens that cause the most deaths. We found that the US would pay $17.9 billion over 30 years but…
New Business Models for Antibiotics
22 April 2014, 11:00pm
Many stakeholders agree that the current business model for antibiotics is broken. Antibiotic innovation has slowed and many of the drugs on the market are losing effectiveness because of resistance….
Biosimilars’ Price Dynamic in Europe
30 June 2010
…seminar and summarises the remarks of Dr Matthias Liefner of Simon Kucher and Partners. In Europe, pricing of biosimilars already has begun to affect the market for biologics. For example, France’s compulsory…
Pricing Variations Within and Across Countries: Gauging Efficiency
25 February 2014
This research explores which approaches to pricing can produce the greatest efficiency and access to medicines within and across countries. OHE collaborated on two articles published in the journal Health…